|
Press Releases
August 25, 2010
Provectus Pharmaceuticals Will Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
will present at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City on September 14, 2010 at 3:15 p.m. Eastern Time.
The conference will be held at the New York Palace Hotel.
Read the complete article here.
July 27, 2010
Provectus Pharmaceuticals to Use Numoda's TruPoints System to Facilitate Transactions with Potential Licensing Partners for PH-10
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
has signed an agreement with Numoda Capital Innovations LLC (http://www.numodacapital.com)
to license its TruPoints strategic partnering platform.
Read the complete article here.
July 15, 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders
KNOXVILLE, Tenn., July 15 --(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
reports on its first half 2010 clinical and corporate accomplishments, as well as its clinical development plans, in a letter to shareholders from Craig Dees, Ph.D.,
CEO of Provectus.
Read the complete article here.
June 07, 2010
Provectus Reports Encouraging Data on Visceral Metastases Presented at ASCO
KNOXVILLE, Tenn., June 7 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in
visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. Sanjiv Agarwala
at the American Society of Clinical Oncology 2010 Annual Meeting, on Sunday, June 6, 2010, in the General Poster Session on Melanoma/Skin
Cancers, Abstract #8534. Positive improvement observed in these remote, untreated lesions, including metastases to the lungs, liver and
brain, illustrate a potential systemic effect in visceral organs to which melanoma has spread. Dr. Agarwala's updated information
included data from both the initial 40 subjects and the final 40 subjects enrolled in the Phase 2 trial.
Read the complete article here.
May 21, 2010
Provectus Reports Further Positive Phase 2 Data on PV-10 for Metastatic Melanoma at ASCO
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an
objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those
subjects achieving an OR.
Read the complete article here.
April 29, 2010
Provectus Reports on Successful End-of-Phase 2 Meeting with U.S. FDA and Gains Clarity for Licensure of PV-10 for Metastatic Melanoma
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical
program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
Read the complete article here.
|
